ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1593

Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis

Vinod Chandran1, Arane Thavaneswaran2 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers and psoriatic arthritis, Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are elevated only in about 50% of patients with active PsA. Neutrophil-Lymphocyte Ratio (NLR) has been recently shown to be a marker of inflammation with prognostic value in inflammatory, cardiovascular and malignant diseases. We therefore evaluated NLR as a marker of disease activity in patients with PsA.

Methods

The study was conducted in a large PsA cohort were patients are seen accordingly to a standard protocol that includes clinical and laboratory assessment. Swollen joint count (SJC) and PASI score were used as  measures of disease activity in PsA at baseline. NLR was calculated from the neutrophil and lymphocyte count obtained from a complete blood count done at the time of clinic assessment. Pearson correlation between NLR and disease activity markers (SJC, PASI) and traditional acute phase reactants [ESR, haemoglobin (Hb), platelet count] were investigated. The association between ESR, Hb, platelet count and NLR with SJC and PASI score was determined using univariate and multivariate linear regression. Since the NLR was not normally distributed, lognormal transformation was done.

Results

1130 (631 males) with a mean age of 45 years, age at onset of psoriasis 29 years and of PsA 38 years were included. At the time of the first assessment these patients had 11 active, 5 swollen and 8 clinically damaged joints and the PASI score was 5.3. The mean ESR was 23 mm/hr, Hb 139 g/dL, platelet count 286,000/microL and NLR 3.2. The NLR significantly correlated with SJC (r=0.12, p<0.0001), PASI (r=0.15, p<0.0001), ESR (r=0.24, p<0.0001), Hb (r= -0.18, p<0.0001) and platelet count (r=0.15, p<0.0001). Multivariate linear regression analysis showed that NLR (β 0.16, p = 0.04) and ESR (β 0.11, p = 0.003) were independently associated with SJC. Similarly, multivariate linear regression analysis showed that NLR (β 0.41, p = <0.0001) and ESR (β 0.11, p = 0.007) were independently associated with PASI score.

Conclusion

NLR has a potential as a marker of disease activity in PsA independent of traditional acute phase reactants. Further evaluation to determine threshold of abnormal values in the context of psoriatic disease, as well as prognostic value in predicting joint damage and cardiovascular disease is required.


Disclosure:

V. Chandran,
None;

A. Thavaneswaran,
None;

D. D. Gladman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutrophil-lymphocyte-ratio-as-a-marker-of-disease-activity-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology